Low levels of CD36 in peripheral blood monocytes in subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study in a Mexican population.

BioMed research international

PubMedID: 25006585

Gómez-Bañuelos E, Martín-Márquez BT, Martínez-García EA, Figueroa-Sanchez M, Nuñez-Atahualpa L, Rocha-Muñoz AD, Sánchez-Hernández PE, Navarro-Hernandez RE, Madrigal-Ruiz PM, Saldaña-Millan AA, Duran-Barragan S, Gonzalez-Lopez L, Gamez-Nava JI, Vázquez-Del Mercado M. Low levels of CD36 in peripheral blood monocytes in subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study in a Mexican population. Biomed Res Int. 2014;2014736786.
UNLABELLED
Patients with rheumatoid arthritis (RA) have a higher risk for atherosclerosis. There is no clinical information about scavenger receptor CD36 and the development of subclinical atherosclerosis in patients with RA. The aim of this study was to evaluate the association between membrane expression of CD36 in peripheral blood mononuclear cells (PBMC) and carotid intima-media thickness (cIMT) in patients with RA.

METHODS
We included 67 patients with RA from the Rheumatology Department of Hospital Civil "Dr. Juan I. Menchaca," Guadalajara, Jalisco, Mexico. We evaluated the cIMT, considering subclinical atherosclerosis when >0.6 mm. Since our main objective was to associate the membrane expression of CD36 with subclinical atherosclerosis, other molecules related with cardiovascular risk such as ox-LDL, IL-6, and TNFa were tested.

RESULTS
We found low CD36 membrane expression in PBMC from RA patients with subclinical atherosclerosis (P < 0.001). CD36 mean fluorescence intensity had negative correlations with cIMT (r = -0.578, P < 0.001), ox-LDL (r = -0.427, P = 0.05), TNFa (r = -0.729, P < 0.001), and IL-6 (r = -0.822, P < 0.001).

CONCLUSION
RA patients with subclinical atherosclerosis showed low membrane expression of CD36 in PBMC and increased serum proinflammatory cytokines. Further studies are needed to clarify the regulation of CD36 in RA.